APLLTD vs KOPRAN: Stock Comparison

Alembic Pharmaceuticals Limited vs Kopran Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Alembic Pharmaceuticals Limited is the larger company by market capitalisation. Alembic Pharmaceuticals Limited shows a lower P/E, a higher ROE and faster revenue growth, while Kopran Limited shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alembic Pharmaceuticals Limited and Kopran Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, APLLTD is more favourable on 11 of 13 scored metrics and KOPRAN on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
APLLTD is the larger company
₹16,030 Cr vs ₹942 Cr
P/E Ratio
APLLTD has a lower P/E
24.3x vs 38.28x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 2.89x
EPS
APLLTD has higher earnings per share
₹34.3 vs ₹3.41
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 1.42%
Revenue Growth (TTM YoY)
APLLTD has faster revenue growth
4.4% vs -3.66%
EPS Growth (TTM YoY)
APLLTD has faster EPS growth
29.2% vs -71.88%
Qtr Sales Growth
APLLTD has stronger quarterly sales growth
4.41% vs -3.03%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAPLLTDKOPRAN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAPLLTDKOPRAN
Live Price₹813.1₹206.27
Day Change-2.46%6.56%
Volume46,76338.55 L
52-Week High₹1,032.7₹219
52-Week Low₹635.8₹107
Distance from 52W High-21.26%-5.81%

Valuation

MetricAPLLTDKOPRAN
Market Cap₹16,030 Cr₹942 Cr
P/E Ratio24.3x38.28x
P/B Ratio2.89x1.86x
EPS₹34.3₹3.41
Book Value₹288.7₹107.35
Dividend Yield1.42%1.59%

Growth

MetricAPLLTDKOPRAN
Revenue Growth (TTM YoY)4.4%-3.66%
EPS Growth (TTM YoY)29.2%-71.88%
Qtr Sales Growth4.41%-3.03%
Qtr Profit Growth40.8%-32.9%

Profitability & Leverage

MetricAPLLTDKOPRAN
ROE13.4%4.85%
ROCE12.6%9.75%
Net Margin8.98%3.78%
Operating Margin15.2%6.58%
Debt to Equity0.25x0.29x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAPLLTDKOPRAN
Promoter Holding69.36% 0.13 pp44.42%
FII Holding4.18% 0.07 pp0.51% 0.06 pp
DII Holding15.94% 0.24 pp0%
Public Holding10.01% 0.18 pp55.06% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alembic Pharmaceuticals Limited and Kopran Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.